OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

医学 易普利姆玛 队列 内科学 无容量 中止 肿瘤科 不利影响 癌症 免疫疗法
作者
Fabrice Barlési,Clarisse Audigier-Valette,Enriqueta Felip,Tudor‐Eliade Ciuleanu,Kevin Jao,E. Rijavec,László Urbán,Jean-Sebastien Aucoin,C. Zannori,Karim Vermaelen,Osvaldo Arén Frontera,Neal Ready,Alessandra Curioni‐Fontecedro,Helena Linardou,Elena Poddubskaya,J.R. Fischer,Iuliana Iordan,Harry J.M. Groen,Rathi N. Pillai,Shang Li
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:14 (10): S214-S215 被引量:48
标识
DOI:10.1016/j.jtho.2019.08.424
摘要

Data are limited for immunotherapy in patients with advanced NSCLC and poor performance status or other comorbidities. CheckMate 817 is a multi-cohort, open-label phase 3b/4 study investigating safety and efficacy of flat-dose nivolumab plus weight-based low-dose ipilimumab in advanced NSCLC. Here we evaluate this regimen as first-line treatment in special populations (cohort A1) and a reference population (cohort A; previously reported). Patients had previously untreated advanced NSCLC. Cohort A1 (n=198) had ECOG PS 2 or ECOG PS 0–1 with 1 of: asymptomatic untreated brain metastases, hepatic or renal impairment, or HIV. Cohort A (n=391) had ECOG PS 0–1. Patients with known EGFR mutations or ALK translocations sensitive to available targeted therapy were excluded from both cohorts. Nivolumab 240 mg Q2W plus ipilimumab 1 mg/kg Q6W was administered for two years or until disease progression/unacceptable toxicity. Safety and efficacy endpoints were assessed; cohort A1 analyses were exploratory. Cohort A1 patients were grouped as: ECOG PS 2 (n=139) and all other special populations (AOSP; n=59). Baseline characteristics were generally balanced between cohorts. Rates of grade 3–4 treatment-related adverse events (TRAEs) were similar between cohorts; within cohort A1, grade 3–4 TRAEs were numerically higher in AOSP versus the ECOG PS 2 subgroup; TRAEs leading to discontinuation were similar across populations (Table). ORR was 25% in cohort A1 (patients with ECOG PS 2, 20%; AOSP, 37%) and 35% in cohort A. PFS was numerically shorter in cohort A1 than cohort A; high TMB (≥10 mut/Mb) and higher PD-L1 expression (≥1% or ≥50%) were associated with numerically longer PFS in both cohorts (Table). First-line flat-dose nivolumab plus weight-based ipilimumab showed a consistent safety profile in special populations with advanced NSCLC, including those with ECOG PS 2. Patients with either high TMB or higher tumor PD-L1 expression appeared to exhibit improved efficacy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王号完成签到,获得积分20
刚刚
负责风华发布了新的文献求助20
刚刚
简荼完成签到,获得积分10
刚刚
1秒前
科研通AI2S的应助被taozhanhua采纳,获得10
1秒前
lmhhh发布了新的文献求助10
1秒前
6yy发布了新的文献求助30
2秒前
小马甲的应助被陶醉平灵采纳,获得10
3秒前
3秒前
4秒前
天天快乐的应助被简荼采纳,获得10
4秒前
5秒前
酥SUSU完成签到,获得积分10
6秒前
6秒前
Oasis完成签到,获得积分10
7秒前
无极微光的应助被王号采纳,获得20
7秒前
小包谷完成签到,获得积分10
8秒前
Bruce_Wayne发布了新的文献求助10
8秒前
8秒前
9秒前
挚友发布了新的文献求助10
9秒前
9秒前
不灵0发布了新的文献求助30
10秒前
天天向上的应助被lmhhh采纳,获得30
10秒前
11秒前
李健的小迷弟的应助被youknowdcf采纳,获得10
11秒前
Jing发布了新的文献求助10
12秒前
哎呦呦仔发布了新的文献求助10
13秒前
wyitong2024完成签到 ,获得积分10
13秒前
molec发布了新的文献求助10
14秒前
赘婿的应助被zhouyang采纳,获得10
14秒前
嘟嘟完成签到,获得积分10
14秒前
陶醉平灵完成签到,获得积分10
14秒前
周澍完成签到,获得积分10
15秒前
16秒前
pphome完成签到,获得积分10
16秒前
今后的应助被Huangzhisong采纳,获得10
17秒前
现代的莺完成签到,获得积分20
17秒前
17秒前
缓慢的飞兰完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011